12:00 AM
Aug 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Alteplase regulatory update

Roche disclosed in its 2Q12 earnings that it withdrew an sBLA to expand the label for Activase alteplase to extend the time window for treatment of acute ischemic stroke (AIS) to 4.5 hours. Activase is currently approved to treat AIS within 3 hours after stroke symptom onset....

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >